What is Roth Capital’s Estimate for CELZ FY2028 Earnings?

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) – Equities researchers at Roth Capital decreased their FY2028 earnings per share estimates for shares of Creative Medical Technology in a report released on Wednesday, February 12th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of $6.02 per share for the year, down from their previous forecast of $6.34. The consensus estimate for Creative Medical Technology’s current full-year earnings is ($3.19) per share. Roth Capital also issued estimates for Creative Medical Technology’s FY2029 earnings at $7.83 EPS.

Creative Medical Technology Stock Up 11.1 %

Shares of NASDAQ CELZ opened at $4.59 on Friday. The firm’s 50-day moving average price is $2.62 and its 200-day moving average price is $3.06. Creative Medical Technology has a 52-week low of $1.96 and a 52-week high of $10.28.

Institutional Investors Weigh In On Creative Medical Technology

A hedge fund recently bought a new stake in Creative Medical Technology stock. Geode Capital Management LLC acquired a new position in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 10,308 shares of the company’s stock, valued at approximately $25,000. Geode Capital Management LLC owned 0.59% of Creative Medical Technology at the end of the most recent reporting period. 1.42% of the stock is owned by institutional investors.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.